ANGLE Develops Androgen Receptor Detection Assay for Prostate Cancer Studies with AstraZeneca

ANGLE plc signs £550,000 agreement with AstraZeneca to develop Parsortix-based Androgen Receptor detection assay for prostate cancer studies. The assay development, expected to complete in Q1 2025, aims to improve treatment and management of prostate cancer.

author-image
Rizwan Shah
Updated On
New Update
ANGLE Develops Androgen Receptor Detection Assay for Prostate Cancer Studies with AstraZeneca

ANGLE Develops Androgen Receptor Detection Assay for Prostate Cancer Studies with AstraZeneca

ANGLE plc, a world-leading liquid biopsy company, has signed a £550,000 large supplier agreement with AstraZeneca to develop a Parsortix-based Androgen Receptor (AR) detection assay for use in prostate cancer studies.

The assay development will take place in ANGLE's UK laboratories, with project completion expected in Q1 2025.

Why this matters: This development has the potential to significantly improve the treatment and management of prostate cancer, which affects millions of men worldwide. The ability to assess androgen receptor status in a minimally invasive manner could lead to more targeted and effective treatments, resulting in improved patient outcomes and quality of life.

The Parsortix system will be used to develop a CTC-based AR assay, which could enable longitudinal, minimally invasive assessment of AR status throughout clinical studies and during follow-up. This development has the potential to transform the assessment of prostate cancer therapeutics, offering the possibility of more personalized treatment approaches and improved patient outcomes.

Prostate cancer is the second most common cancer in men, with 1.5 million new cases diagnosed globally each year and 5 million men living with the disease. The androgen receptor plays a crucial role in prostate cancer tumor growth and progression, with anti-androgen therapy frequently given as first-line treatment.

However, response is variable, and 20-30% of patients go on to develop resistance, resulting in disease progression and the development of metastatic castration resistant prostate cancer (mCRPC), which is currently incurable.

ANGLE's Chief Executive Officer, Andrew Newland, commented on the significance of this agreement: "This is further validation of ANGLE's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market." The company anticipates that success in this first phase of assay development may lead to much larger contracts for use of the assay in clinical trials.

Karen Miller, ANGLE's Chief Scientific Officer, expressed her enthusiasm for the project: "We are delighted our expertise is being put to use in the isolation, harvest, and profiling of CTCs for androgen receptor investigation with the potential for ANGLE's assays to be used in clinical trials." The new androgen receptor assay will also be an important addition to the menu of assays ANGLE can offer other customers.

This agreement follows an earlier announcement on April 24, 2024, of a separate agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response (DDR) assay. The successful development of the Parsortix-based AR detection assay could open up new avenues for prostate cancer research and treatment, providing valuable insights into patient response to therapy and disease progression.

With over 130 active, interventional oncology clinical studies in 30,000 participants, which include androgen receptor assessment, registered on clinicaltrials.gov, the potential impact of this assay development is significant. The ability to assess AR status throughout clinical studies and during follow-up in a minimally invasive manner could lead to more targeted and effective treatments for prostate cancer patients.

The successful development of the Parsortix-based AR detection assay represents a major breakthrough in the fight against prostate cancer. By enabling longitudinal, minimally invasive assessment of AR status, this assay has the potential to significantly transform and improve the assessment of prostate cancer therapeutics, leading to enhanced patient outcomes. As Andrew Newland stated,"This is further validation of ANGLE's Parsortix system which shows potential for long-term large-scale revenues in bringing innovative new cancer drugs to the market."

Key Takeaways

  • ANGLE plc signs £550,000 agreement with AstraZeneca to develop Parsortix-based AR detection assay.
  • Assay aims to improve prostate cancer treatment and management through minimally invasive AR status assessment.
  • Parsortix system to be used for CTC-based AR assay development, enabling longitudinal AR status assessment.
  • Prostate cancer affects 1.5 million men globally each year, with 20-30% developing resistance to anti-androgen therapy.
  • Successful development could lead to larger contracts and revenue opportunities for ANGLE plc.